TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance

NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that its board of directors has authorized a reverse stock split of the Company’s common stock at a ratio of 1 post-split share for every 100 pre-split shares. The Company’s common stock will begin trading on a split-adjusted basis upon market open on Tuesday, S